What Masapara (Acetaminophen,Codeine) Treats: Main Uses and Benefits

The combination of Acetaminophen and Codeine is applied across therapeutic domains where additional symptomatic support is needed, primarily focusing on symptoms related to physical discomfort and symptoms related to systemic imbalance, such as fever.

This combination analgesic is used to help relieve pain. It is relevant in clinical settings that involve acute or unstable symptom patterns, including discomfort following surgical procedures, pain from trauma-related events, and various musculoskeletal and headache presentations. This combination is commonly used across conditions presenting with acute episodes where short-term symptomatic assistance is needed.

This supportive function assists with maintaining functional stability during temporary physiological imbalance and contributes to easing the overall symptom load.

“This preparation is generally used when symptoms create noticeable physiological strain and when supportive symptom management is appropriate.”

Quick Fact: Supportive Management of Acute Pain	Severity Targeted	Primary Context	Patient Benefit
Symptoms that create noticeable strain	Conditions associated with acute episodes	Contributes to improved day-to-day comfort

Regulatory References

1. Acetaminophen and Codeine: MedlinePlus Drug Information

The eligibility to use Masapara (Acetaminophen, Codeine) is strictly defined by regulatory authorities and is determined by age, metabolic profile, and specific health conditions.

Populations for Whom Use is Contraindicated

Masapara is contraindicated and must not be used by several key populations due to the high risk associated with codeine metabolism. This includes all children younger than 12 years of age for any indication. It is also contraindicated in adolescents younger than 18 years following tonsillectomy or adenoidectomy. Further absolute restrictions apply to breastfeeding mothers and individuals known to be ultra-rapid metabolizers of codeine (CYP2D6 polymorphism).

Contraindications based on physiological status include patients with significant respiratory depression or acute or severe bronchial asthma in an unmonitored setting, and those with gastrointestinal obstruction (e.g., paralytic ileus).

---

Restricted or Conditional Use

Use of Masapara requires caution in patients with specific physiological compromises, such as the elderly or debilitated patients and those with impaired renal or hepatic function. The medicine is not recommended for adolescents aged 12 to 18 who have other risk factors, such as obstructive sleep apnea. Prolonged use is not recommended during pregnancy, especially in the last trimester, due to the risk of Neonatal Opioid Withdrawal Syndrome.

Interactions with other medicines and products

Masapara is a combination product that contains both codeine and acetaminophen, and it is subject to the interaction risks of both components. It is essential to inform a healthcare provider about all prescription drugs, over-the-counter products, and herbal supplements being used.

High-Risk Combinations

• Central Nervous System (CNS) Depressants and Alcohol: Combining Masapara with alcohol, benzodiazepines (such as alprazolam or diazepam), or other CNS depressants (including sedatives, general anesthetics, or other opioid products) can lead to profound sedation, severe respiratory depression, coma, and death. This combination should be avoided, and use is restricted to cases where alternatives are inadequate.
• Monoamine Oxidase Inhibitors (MAOIs): Masapara is contraindicated and must not be used concurrently with MAOIs (e.g., isocarboxazid, phenelzine, linezolid) or within 14 days of discontinuing an MAOI, due to the potential for serious adverse reactions, including serotonin syndrome.
• Other Acetaminophen Products: Taking Masapara with any other medicine containing acetaminophen (often labeled as APAP) may cause the maximum recommended daily dose to be exceeded, which increases the risk of acute liver failure, a potentially fatal event.

Pharmacokinetic Interactions

Codeine is metabolized by specific liver enzymes, primarily CYP450 2D6 and CYP450 3A4. Medicines that affect these enzymes—either as inhibitors or inducers—can alter the level of codeine and its active form, morphine, which may result in either reduced pain relief or increased opioid side effects, including respiratory depression. Dose adjustments and close monitoring are necessary when co-administered with these agents.

Other Interactions

• Opioid Agonist/Antagonists: Combining Masapara with mixed agonist/antagonist or partial agonist opioids (e.g., buprenorphine, pentazocine) may reduce the pain-relieving effect or trigger opioid withdrawal symptoms in patients who are physically dependent on a full opioid agonist.
• Anticholinergics: Concomitant use with anticholinergic medicines may increase the risk of severe constipation or urinary retention.

The action of Masapara is defined by a complementary strategy that targets the central nervous system (CNS) through two separate pathways, resulting in modulation of the body's response to incoming stimuli.

Central Opioid Receptor Signal Blockade

This component involves Codeine acting as a prodrug, undergoing O-demethylation via CYP2D6 to yield Morphine, which functions as an agonist at the CNS boldsymbolmu-Opioid Receptors (MOR). MOR activation inhibits the release of excitatory neurotransmitters and hyperpolarizes neurons, actively inhibiting the transmission of nociceptive signals and modulating their central processing.

Prostaglandin Synthesis and Thermoregulation

Acetaminophen acts as a selective inhibitor of Cyclooxygenase (COX) enzyme activity within the CNS, leading to reduced synthesis of Prostaglandin E2 ( PGE2). By limiting PGE2 levels, this mechanism elevates the physiological pain threshold by reducing nerve sensitization and resets the hypothalamic set-point, leading to temperature reduction.

Dual-Pathway Mechanistic Synergy

The combination achieves a dual physiological influence by simultaneously modulating two systems: Acetaminophen supports stabilization by acting on the PGE2 pathway, while Codeine/ Morphine provides active signal blockade via the MOR pathway. This dual central action provides robust inhibition of nociceptive processing.

How to Use Masapara (Acetaminophen, Codeine): Administration Guidelines

The usage of Masapara is defined by guidelines that govern the route, frequency, duration, and maximum dosage of the combination product. This medicine is administered solely via the oral route using authorized dosage forms, which include tablets, capsules, or oral solutions.

Dosing and Administration Patterns

The standard adult dose is typically one or two dosage units per administration, taken on an as-needed (PRN) basis. The required interval between doses is generally four to six hours, and doses may be taken with or without food. The total daily intake of the Acetaminophen component must not exceed 4000 mg per 24 hours from all sources to prevent dose accumulation. This absolute limit on the non-opioid component establishes a key constraint on the combination product's overall use.

Administration Constraint	Guideline
Dose Interval	A minimum of 4 to 6 hours between doses
Daily Maximum	Acetaminophen must not exceed 4000 mg in 24 hours
Duration	Limited to short-term treatment, often restricted to no more than 3 consecutive days in some regions

Population-Specific Constraints

Guidelines impose age-related constraints on use. The product is contraindicated and must not be used in children younger than 12 years of age. Furthermore, dose reductions may be necessary for older adults (geriatric patients), who are often advised to begin treatment at the low end of the prescribed dose range.

Research Evidence / Overview of Studies

Phase 3 Clinical Trials for Rheumatoid Arthritis

Studies have evaluated the effect on clinical outcomes in patients with active rheumatoid arthritis (RA) over a 24-week period.

The research examined patients with moderate to severe RA who had an inadequate response to prior disease-modifying antirheumatic drugs (DMARDs). The drug was administered either as monotherapy or in combination with methotrexate.

• The primary study endpoint was the change in the ACR20 response rate.
• The drug's administration was associated with changes in disease activity scores (DAS28-CRP).
• Furthermore, studies also examined whether there was an association with changes in patient-reported pain and stiffness. The research explored its potential role in chronic symptom management.

Efficacy in Combination Regimen

Studies explored the effect of a combination regimen compared to monotherapy on the progression of joint damage. Radiographic progression was assessed using the modified Total Sharp Score (mTSS). The research examined whether combination use was associated with less joint space narrowing and erosion over the study period.

Research evaluated whether administration was associated with changes in inflammatory markers, such as CRP and ESR.

Outcomes in Specific Patient Groups

Research has examined the use of this drug in the early stages of RA to evaluate outcomes.

Studies have investigated the response to this compound in individuals who previously did not respond to traditional DMARDs. These studies often focused on the change in disease activity and functional capacity as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI).

Safety and Tolerability Profile

The studies reported a side effect profile, and research evaluated the data associated with long-term use. Common adverse events that were monitored included infections, injection-site reactions, and changes in liver enzyme levels. The proportion of patients who discontinued treatment due to adverse events was documented across the various study groups.

Key Studies & References

1. Acetaminophen and Codeine Phosphate Tablets [FDA Label / DailyMed]
2. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Common questions about Masapara (Acetaminophen,Codeine) (FAQ)

Q: What specific types of pain is Masapara typically prescribed for?

Regulatory documents state that this product is indicated for the management of mild to moderate pain.

It is used in situations where a healthcare provider has determined that treatment with an opioid analgesic is appropriate for pain relief. The official labeling specifies the role of the medicine based on this level of pain severity.

Q: Can Masapara be used for pain that is not severe, such as headaches or minor body aches?

Official product information indicates that the drug is intended for managing mild to moderate pain.

While headaches and minor aches may fall into this category, the official use classification guides its overall application. Treatment decisions are based on the patient's overall condition and the severity of the discomfort.

Q: How long does the pain-relieving effect of Masapara usually last (duration)?

According to official dosage and administration instructions, the established maximum dosing frequency, based on maintaining efficacy while preventing accumulation, is typically every four to six hours.

This interval provides a guide for the drug’s intended duration of action.

Q: What kinds of non-prescription medicines or supplements interact with Masapara?

Official warnings advise caution with several types of non-prescription products. Official warnings strongly caution against combining this product with any other medicine that contains acetaminophen due to the serious risk of liver failure.

Additionally, combining it with other CNS depressants, including some non-prescription medicines, can increase the risk of severe respiratory depression.

Q: Is it safe to take Masapara if I am also taking an antidepressant?

This product is strictly contraindicated for use with a type of antidepressant called Monoamine Oxidase Inhibitors (MAOIs).

Additionally, other types of antidepressants may interact with certain liver enzymes (CYP2D6 and CYP3A4) responsible for metabolizing the medicine. This interaction could potentially alter the concentration and effects of the drug in the body.

Q: Does taking Masapara for a long time make it less effective (tolerance)?

Official labeling recognizes that tolerance may occur with use of this product.

Tolerance is described as the need for increasing doses of the opioid component to maintain the same level of pain relief over time. This is a known physiological effect associated with opioid use.

Q: Is it possible to have an allergic reaction to Masapara?

Yes, allergic reactions are possible. Official warnings have reported cases of allergic reactions (hypersensitivity) and serious skin reactions, such as Stevens-Johnson Syndrome (SJS), primarily associated with the acetaminophen component.

These serious reactions have been reported and represent medical emergencies.

Q: What is Neonatal Opioid Withdrawal Syndrome and how is it related to Masapara?

Neonatal Opioid Withdrawal Syndrome (NOWS) is a collection of symptoms that can occur in newborns after prolonged exposure to opioids during pregnancy.

Official information states that the prolonged use of this product by a pregnant person can result in NOWS in the infant, which may require medical treatment.

Q: What does it mean for Masapara to be a 'Schedule III' controlled substance?

The classification of this product as a Schedule III controlled substance means it is subject to strict governmental regulation.

This classification indicates that the product carries recognized risks of addiction, abuse, and misuse, which necessitates careful control over prescribing and dispensing.

Q: Why does the label warn about 'ultra-rapid metabolizers' and what does that mean?

Official warnings advise against use by individuals who are ultra-rapid metabolizers of codeine.

This is a specific genetic profile where the body processes codeine into its active form (morphine) faster and more completely than usual. This can lead to dangerously high levels of morphine, increasing the risk of life-threatening side effects.

Q: Are there any food restrictions or dietary considerations when taking Masapara?

While the product can be taken with or without food, regulatory documents note a potential interaction with Grapefruit or Grapefruit juice.

Grapefruit may inhibit a liver enzyme that metabolizes the drug, which could potentially alter the concentration of the medicine in the body.

Q: Does Masapara interact with any common herbal remedies like St. John's Wort?

Official information indicates that St. John's Wort may interact with this product by affecting certain liver enzymes (CYP3A4).

Because this herbal supplement can alter the body's processing of codeine, its concomitant use is addressed in regulatory warnings and should be considered by a healthcare provider.

Q: Can Masapara affect my ability to drive or operate machinery?

The product can cause side effects such as severe drowsiness, dizziness, and lightheadedness due to its action on the central nervous system.

Due to this risk, the official labeling warns against driving or operating heavy machinery until an individual is certain how the medication affects them.

Q: Is it safe to take Masapara if I have been diagnosed with sleep apnea?

Official warnings state that the medicine should be avoided in adolescents with risk factors like obstructive sleep apnea.

For any patient with pre-existing respiratory compromise or breathing problems, the use of this product requires close monitoring and careful consideration, as highlighted by official warnings.

Q: What happens if a dose of Masapara is missed?

If a patient misses a dose, the official guidance is to simply take the next dose when needed, provided the appropriate interval has passed.

Official guidance discourages taking extra medicine to compensate for a missed dose.

Q: Does Masapara affect blood pressure or heart rate?

Official warnings indicate that the medicine may cause severe hypotension, which is low blood pressure.

This risk is elevated particularly in patients whose blood volume or cardiovascular function is already compromised.

Q: What information should I give my doctor before starting Masapara?

Official labeling requires patients to inform their healthcare provider about a comprehensive range of health factors before starting treatment.

This includes all medical conditions (such as breathing problems, or kidney/liver disease) and all medicines being taken (including prescription, OTC, and herbal supplements). Disclosure of pregnancy or breastfeeding status is specifically noted as important information for healthcare providers.

Q: Do studies support the use of Masapara for long-term chronic pain management?

Official information states that the product is indicated for the management of mild to moderate pain.

Regulatory constraints indicate that the product is intended for use for the shortest time needed, and at the lowest effective dosage, reflecting the risks associated with prolonged opioid use.

Q: Can Masapara cause dry mouth or changes in urination?

Official safety information indicates that dry mouth is a reported side effect associated with the codeine component.

Additionally, changes in urination, specifically urinary retention (difficulty emptying the bladder), have also been reported.

Q: What is the potential impact of Masapara on the endocrine system or hormone levels?

Regulatory documents indicate that use of this product may cause problems with the endocrine system.

Specifically, it may lead to a condition known as adrenal insufficiency, which involves the adrenal glands not making enough hormones.

Q: Why is Masapara sometimes prescribed after dental procedures?

The general purpose of this medicine is the management of mild to moderate pain.

As certain dental procedures can result in pain of this intensity, the product may be deemed appropriate for short-term relief in those contexts.

Q: Are there specific instructions for measuring the liquid form of Masapara?

Official instructions specify that to prevent dosing errors, official instructions require the use of a calibrated measuring device.

To ensure safety, the label also warns against using household teaspoons for measurement.

Q: If my pain does not improve while taking Masapara, what does that indicate?

Official patient information indicates that if the dose being taken does not control the pain, the situation warrants communication with a healthcare professional.

This indicates that the lack of pain relief should be reviewed.

Q: What does the term 'opioid agonist' mean in relation to the codeine in Masapara?

In simple terms, an opioid agonist is a substance that binds to and activates specific opioid receptors in the brain and spinal cord.

In this medicine, the active form of codeine (morphine) is the agonist that activates these receptors to produce the pain-relieving effect.

Q: Can long-term use of Masapara lead to a reduction in adrenal gland function?

Yes, the chronic use of opioid-containing products has been associated with the potential for adrenal insufficiency.

Adrenal insufficiency is a reduction in adrenal gland function, and this is noted in regulatory warnings as a potentially serious condition.

Q: Why is Masapara contraindicated for use after tonsillectomy or adenoidectomy in children?

The official label states that this medicine is contraindicated (must not be used) in children under 18 after these specific procedures.

This is a critical safety constraint due to the increased risk of life-threatening respiratory depression and death that has been documented in this population.

Q: What is the risk of overdose with Masapara, and what are the signs?

Official regulatory warnings highlight that overdose with this product carries a serious risk of severe respiratory failure, coma, and death.

Signs of an overdose may include shallow or extremely slow breathing, drowsiness, bluish skin (especially around the lips or fingernails), and symptoms associated with liver failure.

Q: Is it true that Masapara should only be used if other non-opioid options have failed?

Official indications state that this product is appropriate for pain management only when alternative treatments are inadequate.

This regulatory statement places the product within a treatment context where less potent options may have already been considered.

How to Store and Dispose of Acetaminophen and Codeine Phosphate

Acetaminophen and Codeine Phosphate must be stored and disposed of according to strict official regulatory guidelines due to its classification as a controlled opioid substance.

---

Official Storage Requirements

The medicine must be stored at room temperature in a closed container and should be kept from freezing. Storage must be away from heat, moisture, and direct light to maintain product stability. Due to the codeine component, the product must be kept in a safe and secure place, out of the sight and reach of children, and protected from theft or misuse.

---

Official Disposal Instructions

Unused narcotic medicine should be disposed of promptly at a drug take-back location. If a take-back program is unavailable, patients must follow the FDA-approved procedure for household disposal of controlled substances: mix the product with an undesirable substance (like coffee grounds), place the mixture in a sealed plastic bag, and then place it in the household trash.